Stay updated on Oral Elsubrutinib and Upadacitinib in Lupus Clinical Trial
Sign up to get notified when there's something new on the Oral Elsubrutinib and Upadacitinib in Lupus Clinical Trial page.

Latest updates to the Oral Elsubrutinib and Upadacitinib in Lupus Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded a new site revision note 'Revision: v3.3.3' and removed the 'HHS Vulnerability Disclosure' link along with the previous 'Revision: v3.3.2' entry. These changes reflect backend/site policy updates rather than alterations to the trial data or history.SummaryDifference0.2%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedAdded revision v3.3.2 and removed revision v3.2.0 from the study record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedRemoved the banner notice about lapse in government funding and NIH operating status from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check70 days agoChange DetectedBoth screenshots display the same version history and study details, with no new content or deletions. The layout appears unchanged and there are no visible edits to core information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedVersion bumped to v3.2.0 with an added government-operating-status notice; the previous v3.1.0 deletion indicates the page now reflects the updated version.SummaryDifference10%

- Check106 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.2%

Stay in the know with updates to Oral Elsubrutinib and Upadacitinib in Lupus Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Elsubrutinib and Upadacitinib in Lupus Clinical Trial page.